Recent major advances in understanding the molecular basis of acute myeloid leukemia
(AML) provide a double-edged sword. Although defining the topology and key features of …

DNA methylation patterns are disrupted in various malignancies, suggesting a role in the
development of cancer, but genetic aberrations directly linking the DNA methylation …

The development of effective treatment strategies for most forms of acute myeloid leukemia
(AML) has languished for the past several decades. There are a number of reasons for this …

Specific combinations of acute myeloid leukemia (AML) disease alleles, including FLT3 and
TET2 mutations, confer distinct biologic features and adverse outcome. We generated mice …

Background Patients with refractory or relapsed haematological malignancies have few
treatment options and short survival times. Identification of effective therapies with genomic …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

Current prognostication in primary myelofibrosis (PMF) is based on the dynamic
international prognostic scoring system (DIPSS)-plus, which employs clinical and …

Acute myeloid leukemia with t (8; 21)(q22; q22) is characterized by considerable clinical and
biological heterogeneity leading to relapse in up to 40% of patients. We sequenced coding …

The TP53 mutation is frequently detected in acute myeloid leukemia (AML) patients with
complex karyotype (CK), but the stability of this mutation during the clinical course remains …

In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …